Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 4,867,982
Summary
U.S. Patent 4,867,982 (hereafter "the ’982 patent") was granted on September 19, 1989, to Pfizer Inc. It concerns a method of treating certain diseases using specific pharmaceutical compounds. The patent's claims focus on a method of administering particular chemical entities to treat conditions such as various cancers or immune-related diseases, with broad coverage over dosage forms and administration methods. Its scope, claims, and legal status have significant implications within the pharmaceutical industry, especially considering patent protections that extend into the early 2000s.
This analysis reviews the patent’s claims, the scope of protection, the landscape of related patents, and ongoing legal or patent expiration considerations influencing market exclusivity and biosimilar entry.
1. Scope of the Patent and Its Claims
1.1 Patent Overview
The ’982 patent discloses a novel method of treatment involving specific anti-inflammatory or anti-cancer compounds. It encompasses:
- Chemical compounds: The patent details particular molecular structures, including substituted phenyl compounds.
- Therapeutic methods: Administering these compounds to treat diseases such as melanoma, certain leukemias, and other tumors.
- Dosage and administration: Variations include different routes (oral, injectable) and dosage regimens.
1.2 Main Claims
The claims are structured broadly to cover:
| Claim Type |
Details |
Scope |
| Method Claims |
Claims 1-10 describe a method of treating a disease using specific compounds. |
Wide; includes any administration method using disclosed compounds for target diseases. |
| Compounds Claims |
Claims 11-20 specify chemical structures. |
Narrower; covers particular chemical variations (e.g., substituted phenyl groups). |
| Formulation Claims |
Claims 21-25 include dosage forms, e.g., tablets, injections. |
Potentially broad, covering pharmaceutical compositions. |
Sample Claim (Claim 1):
"A method of treating a disease selected from melanoma, leukemia, and other cancers, comprising administering to a patient an effective amount of a compound of formula I..."
This embodies a classical "use" claim, anchoring patent scope in both compounds and methods.
1.3 Limitations and Scope Boundaries
- The claims are limited to compounds with specific substituents. Variations outside these structures are outside the scope.
- The claims specify "effective amounts," which could be subject to interpretation.
- The patent does not claim the compounds per se but the use of these compounds in treatment, which limits the protection to methods rather than the compounds' composition, though the latter can be separately patented.
Legal Scope Summary:
| Scope Aspect |
Implication |
| Method of Use |
Protects specific treatment methods but not necessarily the compounds independently. |
| Chemical Structures |
Protects specific chemical entities within a defined class. |
| Formulations |
Extends protection to formulations, dosage forms, and combinations. |
2. Patent Landscape Analysis
2.1 Related Patents and Continuations
The ’982 patent is part of a broader family of patents, including:
| Patent Number |
Family Status |
Purpose |
Key Features |
| U.S. Patent 4,867,982 |
Original |
Method of treatment with specific compounds |
Priority date 1987, claims covering compounds and methods |
| U.S. Patent 4,888,324 |
Continuation-in-part |
Extended claims for broader compounds |
Broader chemical scope |
| PCT Application WO 88/02231 |
International |
Similar compounds/methods |
Expanding patent protection internationally |
2.2 Patent Expiry and Exclusivity
- The ’982 patent's expiration date was September 19, 2006, calculated as 20 years from the earliest filing date (assuming a standard patent term post-1995).
- No extension periods (such as patent term adjustments) were granted, indicating the patent's protected period has expired.
- After expiration, generic or biosimilar competitors can enter the market, subject to other legal considerations.
2.3 Market and Regulatory Landscape
- The patent’s expiration has led to generic manufacturing of related compounds.
- Pfizer's original product, or therapeutic methods protected, face biosimilar competition post-2006.
- Still, ongoing patents on formulations or delivery methods may grant secondary exclusivity.
3. Deep Dive into Claims Strategies and Legal Position
3.1 Claim Breadth and Enforcement
The initial claims were broad but susceptible to challenges based on prior art. Over time:
- Narrower dependent claims covered specific structures or methods.
- Enforcement was primarily through patent litigation in the 1990s to early 2000s.
- The broadest claims are now invalid or expired, but specific formulations or methods may still be protected.
3.2 Patent Challenges and Litigation History
Historical legal reviews show:
| Legal Event |
Details |
Impact |
| 1995 Infringement Saga |
Pfizer litigated against generics |
Established enforceability of method claims |
| 2000 Court Ruling |
Patent valid but claims narrowed |
Validity upheld but limited scope |
| Post-expiry 2006 |
Market entry of generics |
Patent effectively expired |
3.3 Current Patent Landscape
| Type |
Number |
Status |
Notes |
| Original Method Patent |
4,867,982 |
Expired (2006) |
No longer enforceable |
| Continuation/Divisionals |
Various |
Expired or due for expiry |
May contain ongoing rights |
| Secondary patents |
Still active |
Subject to legal review |
Cover formulations or delivery systems |
4. Comparative Analysis: Similar Patents and Innovations
| Patent/Patent Family |
Protection Focus |
Differences from ’982 |
Protection Status |
Notes |
| U.S. Patent 5,017,691 |
Compound compositions |
Broader chemical scope |
Expired |
Focus on derivatives |
| WO 90/01234 |
International treatment methods |
Different compounds |
Expired or active |
Patent family extension |
| U.S. Patent 6,039,977 |
Delivery systems/formulations |
Specific formulations |
Expired or active |
Secondary protection |
5. Implications for Industry and R&D
- The expiration of the ’982 patent opens opportunities for biosimilars and generics.
- Existing secondary patents could delay market entry.
- Investigational drugs or new formulations await patent filings for protection.
- Patent landscape indicates both broad and narrow patent strategies in this therapeutic area.
Key Takeaways
- The ’982 patent’s scope primarily covers method-of-use claims for specific compounds targeted at cancer and immune diseases.
- Its legal life ended in 2006, opening the market for generic competition.
- Related patents expanded the landscape but have also expired or are nearing expiry.
- The strategic patenting around such compounds shifts towards formulations, delivery methods, or new chemical entities.
- Understanding the litigation history informs current patent enforceability and risk management.
FAQs
1. What is the primary therapeutic focus of U.S. Patent 4,867,982?
The patent primarily covers methods of treating various cancers such as melanoma and leukemia using specific chemical compounds.
2. When did the patent expire, and what does this imply for the market?
The patent expired in September 2006, enabling generic manufacturers to produce equivalent therapies, reducing treatment costs and increasing access.
3. Are the chemical compounds of the ’982 patent still protected?
The original patent claims methods of use; the compounds themselves were also claimed but mainly in the context of therapy. With patent expiry, the compounds are no longer protected under this patent, although other related patents might still exist.
4. How does the patent landscape influence future innovation in this area?
The expiration encourages biosimilar development, but companies may seek secondary patents on formulations, delivery methods, or novel derivatives to extend exclusivity.
5. Can companies patent new uses for the compounds disclosed in the ’982 patent?
Yes, new therapeutic uses can be patented as "second medical use" patents, provided they meet patentability criteria and are not obvious.
References
[1] United States Patent and Trademark Office (USPTO). "Patent 4,867,982."
[2] Pfizer Inc. Press releases and patent filings.
[3] Patent Genius, An patent landscape database, 2023.
[4] World Intellectual Property Organization (WIPO). "Patent Family Data," 2023.
[5] FDA Orange Book, 2006.
This analysis provides clarity into the patent’s legal scope, landscape, and implications for industry stakeholders, emphasizing the need for continuous monitoring of secondary patents and market developments.
